• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Increasing the Folic Acid Dose for Women Who Smoke: Does it Reduce the Risk of Fetal Growth Restriction?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Previous studies have demonstrated
    • An association between smoking and fetal growth restriction
    • An association between smoking and low maternal folic acid levels
  • Yusuf et al (JAMA Pediatrics, 2019) sought to determine the efficacy of higher-dose folic acid to prevent reduction in fetal size among smokers

METHODS:

  • Randomized clinical trial (RCT)
  • Participants
    • Active smokers based on self-report and cotinine biomarker
    • Aged 18-44 years
    • <21 weeks at study entry
  • Exposures
    • Higher-dose group: 4 mg of folic acid per day
    • Standard-dose group: 0.8 mg of folic acid per day
  • Both study groups received counseling on smoking cessation
  • Primary outcomes
    • Infant birth weight
    • Infant status as small of gestational age (SGA): Defined as weights <10th percentile of birthweight for their GA
    • Fetal growth restriction (FGR): Defined as fetal growth ratio <0.85 (ratio = observed birthweight to expected mean birthweight based on GA)
  • Data analysis
    • Estimated relative risk of SGA birth and FGR
    • Estimated mean differences in birth weight
    • Regression models used to account for confounding

RESULTS:

  • Intention-to-treat analysis was based on 312 study participants
  • Study population
    • Baseline characteristics in both treatment groups were well matched except race
      • 11.1% in high dose vs 21.8% in low dose group were of ‘other’ race (neither white and black)
      • Variable controlled for in analyses
  • Mean (SD) birthweight: 3059.0 (640.2) g | Incidence of SGA: 23.7% | Incidence of FGR: 29.2%
  • Higher dose folic acid was associated with
    • Increased birthweight: Adjusted mean difference: 140.39g (95% CI, 1.63-279.15)
    • Decreased risk for FGR: RR 0.65 (95% CI, 0.46-0.93)
  • For SGA, higher-dose group had a 31% lower risk of small for gestational age, but result was not statistically significant
  • There was no elevated risk of adverse effects associated with higher-dose folic acid

CONCLUSION:

  • Women who smoked but received higher-dose folic acid supplements had a statistically significant increase in birth weight
  • Higher-dose folic acid group were also 35% less likely to have FGR
  • The authors suggest that higher doses of folic acid may be a safe and effective way to minimize fetal growth risks for women who continue to smoke during pregnancy

Learn More – Primary Sources:

Comparing Folic Acid Dosage Strengths to Prevent Reduction in Fetal Size Among Pregnant Women Who Smoked Cigarettes

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Does Smoking During Pregnancy Affect the Fetal Immune System?
Reduced Risk of Autism in Offspring Exposed to Folic Acid During Pregnancy
Does Folic Acid Decrease Preeclampsia Rates in Those at Risk?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site